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Abstract: Type 2 diabetes (T2D) and obesity are common chronic disorders with multifactorial
etiology. In our study, we performed an exome sequencing analysis of 110 patients of Russian
ethnicity together with a multi-perspective approach based on biologically meaningful filtering
criteria to detect novel candidate variants and loci for T2D and obesity. We have identified several
known single nucleotide polymorphisms (SNPs) as markers for obesity (rs11960429), T2D (rs9379084,
rs1126930), and body mass index (BMI) (rs11553746, rs1956549 and rs7195386) (p < 0.05). We show
that a method based on scoring of case-specific variants together with selection of protein-altering
variants can allow for the interrogation of novel and known candidate markers of T2D and obesity
in small samples. Using this method, we identified rs328 in LPL (p = 0.023), rs11863726 in HBQ1
(p = 8 × 10−5), rs112984085 in VAV3 (p = 4.8 × 10−4) for T2D and obesity, rs6271 in DBH (p = 0.043),
rs62618693 in QSER1 (p = 0.021), rs61758785 in RAD51B (p = 1.7 × 10−4), rs34042554 in PCDHA1
(p = 1 × 10−4), and rs144183813 in PLEKHA5 (p = 1.7 × 10−4) for obesity; and rs9379084 in RREB1
(p = 0.042), rs2233984 in C6orf15 (p = 0.030), rs61737764 in ITGB6 (p = 0.035), rs17801742 in COL2A1
(p = 8.5 × 10−5), and rs685523 in ADAMTS13 (p = 1 × 10−6) for T2D as important susceptibility loci
in Russian population. Our results demonstrate the effectiveness of whole exome sequencing (WES)
technologies for searching for novel markers of multifactorial diseases in cohorts of limited size in
poorly studied populations.
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1. Introduction
Type 2 diabetes (T2D) and obesity are common chronic disorders with multifactorial etiology.
Due to their rising prevalence, they are recognized as a global epidemic by the World Health
Organization (WHO) [1–4]. Clinically, T2D is a metabolic disorder characterized by insulin resistance
and pancreatic β-cell dysfunction because of uncontrolled hyperglycemia [5]. T2D can seriously
impair overall quality of life and lead to a long list of complications, including heart disease, stroke,
kidney failure, neuropathy, blindness, and extremity amputation [4,6]. Obesity is a heterogeneous
disorder that can be defined as abnormal or excessive fat accumulation that may impair health.
Excessive weight and obesity are strongly correlated with T2D. They can lead to adverse metabolic
effects on blood pressure, cholesterol, triglycerides and insulin resistance. According to WHO,
excessive weight and obesity account for 44% of diabetes cases [7,8]. Because of this close
relationship, T2D and obesity can be considered as associated pathologies with a potential common
genetic component.
In the recent years the understanding of etiology of these disorders has improved dramatically and
genetic high-resolution technologies allowed the identification of 128 susceptibility genetic markers of
T2D and more than 700 markers for increased body mass and obesity [4,9–11]. The genetic architecture
of T2D and obesity was elucidated mostly using genotyping array data to conduct large-scale genome
wide association studies (GWAS) [9–11]. Despite having high statistical power to detect genetic
associations, GWAS-derived single nucleotide polymorphisms (SNPs) themselves do not usually have
any impact on complex traits; rather, they are in high linkage disequilibrium (LD) with the real causal
variants for the disease. Such causal variants must be finely mapped using imputation methods before
making any functional assumptions. Importantly, many complex traits are shaped by a complex
interplay between common and rare variants, with the latter usually being missed by conventional
GWAS approaches.
Next-generation sequencing (NGS) technologies have become an important instrument in
identifying genetic causes of monogenic diseases. Advances in the application of this method are
due to two reasons: Reduction in the cost of analysis and development of effective bioinformatics
methods. It has been shown that the exome sequencing allowed to identify up to 42% causes of
monogenic and oligogenic diseases [12]. However, despite the rapid spread of NGS methods in
diagnosis of hereditary diseases, the cost-efficiency of whole-exome and whole-genome sequencing
technologies for unveiling the risk factors of complex diseases is still being debated. Exome sequencing
of large cohorts has provided important insights into the role of rare coding variants in T2D and
obesity [13,14]. However, whole exome sequencing (WES)-based association studies usually suffer
from sample size limitations, as thousands of sequenced individuals are usually required to detect
exome-wide significant loci, especially for highly polygenic traits. As such, the application of exome
sequencing to the analysis of complex traits requires large-scale research efforts and/or development of
special methods of bioinformatics analysis. On the other hand, a traditional GWAS approach implying
the use of genotyping arrays is cheaper but requires additional studies, such as fine-mapping of causal
variants, to get insights into the pathogenesis of complex diseases.
Given these limitations of modern approaches, we developed and applied a multi-perspective
approach together with biologically meaningful filtering criteria to detect novel candidate variants
and loci for T2D and obesity in a moderate-sized cohort of Russian patients.
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2. Materials and Methods
The study was approved by the Review Board of City Hospital No. 40 (Protocol 119, 09.02.2017)
Saint-Petersburg and Biobank of Center for Preventive Medicine (Protocol No. 02-05/15, 10.03.2015,
and No. 05-05/15, 09.06.2015), Moscow. Written informed consent of the patients was obtained
before collecting the samples and processing the medical history data. The study was performed in
accordance with the Declaration of Helsinki.
2.1. Patients
The study comprised 110 participants. All patients were interviewed to obtain their family history
of T2D mellitus and obesity, as well as ethnicity. Height, weight, and waist and hip circumferences
were recorded for each patient, and body mass index (BMI) and waist-hip ratio (WHR) was calculated.
Fasting glucose and lipid concentrations in the plasma were measured for each study participant.
All patients were divided into three groups: 21 patients with obesity (age 55.76 ± 8.6 years, 61.9%
male, BMI 43.05 ± 5.7 kg/m2), 49 patients with obesity and T2D (age 50.21 ± 10.82 years, 34.7% male,
BMI 32.10 ± 8.92 kg/m2) and 40 patients of the control group (age 56.44 ± 10.8 years, 52.5% male,
BMI 22.56 ± 1.85 kg/m2) who met the inclusion criteria for analysis. The main clinical characteristics
of the donors are given in Table 1. All patients were of Russian ethnicity.
Table 1. Basic characteristics of study participants of Russian ethnicity.
Characteristic Control Group(n = 40)
Obesity Group
(n = 21)
T2D (with Obesity)
(n = 49)
Age (years) 56.44 ± 10.8 55.76 ± 8.60 50.21 ± 10.82
Male 52.5% 61.9% 34.7%
Ethnicity Russian Russian Russian
BMI (kg/m2) 22.56 ± 1.85 43.05 ± 5.70 32.10 ± 8.92
Family History (based on the results of the questionnaire)
Family history of obesity no (40/40) yes (21/21) yes (49/49)
Family history of T2D no (40/40) yes (21/21) yes (49/49)
Family history of other endocrine pathologies no (40/40) yes (21/21) yes (49/49)
BMI: body mass index; T2D: type 2 diabetes.
2.2. DNA Isolation
DNA samples from the blood of all patients were isolated by fenol extraction [15].
DNA concentration was determined using Quantus Fluoremeter™ and QuantiFluor® dsDNA System
(Promega Corporation, Madison, Wisconsin, USA). DNA integrity was verified using electrophoresis
in 0.6% agarose gel in SB buffer.
2.3. Library Preparation and Exome Sequencing
Libraries were constructed using the TruSeq® Exome Library Prep kit (Illumina Inc., San Diego,
California, USA) according to the TruSeq Exome Library Prep Reference Guide, Document # 15059911
v01 (Illumina Inc.). Alternatively, libraries were constructed using NimbleGen SeqCap EZ Med Exome
Enrichment Kit (Roche NimbleGen Inc., Wisconsin, USA) according to the SeqCap EZ Library SR
User’s Guide v. 5.1. Validation of the libraries was performed on the QIAxcel Advanced System
(Qiagen, Hilden, Germany). Library quantification was performed using Quantus Fluoremeter™ and
QuantiFluor® dsDNA System (Promega Corporation). Paired-end sequencing of the libraries was
performed on HiSeq 4000 System or HiSeq 2500 System (Illumina Inc.). An average sequencing depth
of 50.3 million reads per sample was obtained, resulting in the mean coverage of targeted regions of
57.0 and an average of 90.3% of targeted bases covered at least 10×.
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2.4. Bioinformatic Analysis
All samples were analyzed using a bioinformatic pipeline based on BWA-MEM v. 0.7.15-r1140 [16],
PicardTools v. 2.2.2 (http://broadinstitute.github.io/picard/) and Genome Analysis ToolKit (according
to the GATK Best Practices workflow [17,18]). Variants were called using GATK HaplotypeCaller
in the emit reference confidence (ERC) GVCF mode. All samples included in the dataset were
jointly genotyped with GATK GenotypeGVCFs tool; variant filtration was done using Variant Quality
Score Recalibration (VQSR) [17] with stringent filtering criteria (SNP and insertion and deletions
(INDEL) sensitivity 90.0). Variant annotation was performed using SnpEff and SnpSift packages [19].
We used dbSNP build 146, ClinVar v. 2018-04-01 and dbNSFP v. 2.9 for variant annotation [20].
Allelic frequency data were obtained from VCF files of 1000 Genomes phase 3 (build 2013-05-02,
http://www.internationalgenome.org/) [21], Exome Aggregation Consortium (ExAC) r. 0.3.1 [22],
and an in-house database of allelic frequencies in the Saint Petersburg State University (SPBU) Biobank
cohort according protocol described earlier [23].
2.5. Statistical Analysis
To run association tests, we used PLINK/SEQ genetics library v. 0.10 ([24]; https://atgu.mgh.
harvard.edu/plinkseq). Given that patients in the dataset were separated into three different groups
(control, T2D and non-diabetic obesity), we considered four possible comparisons throughout the
binary trait analysis (obesity vs. control, T2D vs. control, T2D vs. obesity + control, and obesity + T2D
vs. control). All that called variants were used for binary trait association tests. Coding T2D and obesity
markers reported in previous exome sequencing and genotyping array-based studies were selected
for replication from [9–11,13,14,25]. For the association analysis of quantitative traits (BMI, WHR,
glucose and triglyceride concentrations), all study participants were pooled together. We removed
extreme outliers for each quantitative trait (i.e., points more than 3 standard deviations away from
the group mean). Association tests for quantitative traits were performed using variants with minor
allele frequency (MAF) > 0.05 in the dataset. The analyses were adjusted for age and sex of the study
participants. For gene-level statistics, we applied burden test for case-unique variants on variants with
MAF ≤ 0.05 in the dataset. GENCODE v19 genome annotation (https://www.gencodegenes.org/)
was used to conduct gene-level tests. In exome-wide analyses, we used 1 × 10−6 as the exome-wide
significance threshold for SNP-level tests and 2.5 × 10−6 for gene-level tests.
To obtain a list of biologically and statistically justified candidate loci for each binary trait given
low statistical power of exome-wide analysis, we considered two groups of variants with the highest
potential of being causal for the phenotypes considered (see Results for additional details):
(i) variants in known genes implicated in T2D [10] and obesity [26] with significant effect
on the corresponding protein (protein-altering variants) (based on the variant type (only
non-synonymous substitutions and coding indels were selected) and pathogenicity prediction
(for missense variants) by SIFT [27], PROVEAN [28] and Polyphen2 [29] packages); (significance
level of 0.05 was applied for these variants)
(ii) low-frequency variants (MAF between 1% and 10% according to SPBU Biobank data) that are
highly specific to the case or control group (see Results for a more detailed analysis of such
variants’ properties). (significance level of 0.001 was applied for case-specific variants).
For selection of case- and control-specific variants, we calculated a set of previously described
additive scores [30]. The scores were calculated as follows: Score1 = 10 × ncase − 50 × ncontrol;
Score2 = 10 × ncontrol − 50 × ncase, where ncontrol is the number of genotypes in control group
(homo-and heterozygous for alternative allele under the dominant model, and strictly homozygous
for the recessive model), and ncase is the number of genotypes in case group. To compare the numbers
of case- and control-specific variants with the random expectation, we performed in silico sampling
experiment in the following way: For each SNP with n non-reference genotypes in a cohort we
conducted n Bernoulli trials with the success probability p = naffected/n. All SNPs with the number of
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successes (k) k = n were scored as expected case-specific. The sampling was performed 10,000 times to
obtain the empirical distributions for the number of group-specific variants.
To obtain estimates of the scoring algorithm performance, we simulated the behavior of variants
with 7000 different combinations of parameters (true population MAF (tMAF) ranging from 0.001
to 0.1 and true odds ratio (tOR) ranging from 1 to 7). The simulations were conducted as follows:
For each pair of parameters, we calculated MAF in control and diseased subpopulation under selected
inheritance model (see supplementary material for detailed description of the procedure). We then
made 100,000 random samples of ncase diseased and ncontrol control individuals from the virtual
Hardy-Weinberg population, with the probability of observing non-reference genotype P = 2AFcontrols
− AFcontrols2 for controls and P = 2AFdiseased − AFdiseased2 for diseased subsample. The number of
non-reference genotypes for each subsample was recorded at each iteration and was used to obtain
empirical positive outcome probability (P (Score1 ≥ 20)) and an expected value of additive score for
each combination of (tMAF, tOR).
To obtain more accurate estimates of false discovery probability for rare causal variants and
account for overrepresentation of such variants in diseased cohort, we calculated MAF-adjusted
p-value as follows: For each variant under consideration, we ran the sampling procedure described
above (with 1,000,000 iterations instead of 100,000) under the tMAF = MAF and tOR = 1 model. The
number of samples in which Score1 value was greater than or equal to the observed one was recorded
and used to calculate the empirical adjusted p-value.
All analyses of genetic association data were performed using R v. 3.4.0 [31]. All code pertinent to
statistical analysis can be found at http://github.com/bioinf/diabetes/.
3. Results
We first sought to replicate previously established associations of coding genetic variants with
T2D, obesity, and quantiatitve traits (BMI, WHR, plasma glucose and triglyceride levels) (Table 2,
Section 1). To this end, we selected coding markers significantly associated with these traits from several
recent WES-based studies and latest GWAS meta-analyses [9–11,13,14,25]. We observed a nominally
significant association for only two T2D markers in RREB1 (Table 2) and PRKAG1, one obesity (OB)
marker in the OR2Y1 gene, and for several BMI markers in the ACP1, RBBP6, and C14orf39 genes.
We went on to explore the association of exome variants with the binary and quantitative
traits considered. No SNPs showed association with both binary and quantitative traits at the
exome-wide significance level (Tables S1–S8). Moreover, we observed almost no association trends
in the distribution of p-value for all phenotypes except BMI (Figures S1 and S2). For the latter one,
we identified rs689452 as the strongest associating SNP (Table 2, Section 2). This variant is located in
the NQO1 gene that is a member of the NAD(P)H dehydrogenase (quinone) family and encodes a
cytoplasmic 2-electron reductase. This enzyme was shown to have a crucial role in protection against
oxidative stress [32]. Furthermore, the rs689452 variant in NQO1 is significantly associated with height
according to the genetic investigation of anthropometric trait (GIANT) consortium [11,33].
Given very small number of markers discovered using variant-level tests, we investigated the
contribution of rare variants (MAF < 5%) using gene-level burden test for case-unique variants.
We observed no genome-wide significant loci with this test, implying that the sample size is insufficient
for both SNP-level and gene-level association tests (Figure S3). As both conventional common
variant (CVA) and rare variants (RVA) association approaches are drastically underpowered to detect
associations in small samples even for quantitative traits, we sought an efficient method to prioritize
candidate marker variants and identify biologically and statistically justified candidates for further
thorough investigation. We decided to make additional further filtration and ranking of variants to
obtain lists of variants which are the most likely candidate markers of the phenotypes concerned.
Filtering and scoring approach has shown its efficiency to detect potential risk variants in other
diseases such as cardiomyopathy in Russian population [30]. In this work we used two previously
described additive scoring approaches to select for case-specific (Score1) and control-specific (Score2)
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variants under dominant and recessive inheritance models (see Statistical analysis section in the
Methods for more details). We first examined the power of such scoring to identify variants with
different combinations of MAF and OR. To this end, we conducted in silico simulations for 7000
different combinations of MAF and OR (see Statistical analysis section in the Methods for algorithm
details). Our analysis showed that scoring for case-specific variants under dominant inheritance model
efficiently prioritizes variants that have low allele frequencies and higher OR, i.e., the ones that have
the highest causal potential for the disease. Such variants have both higher probability of positive
test outcome (two or more case-specific observations) and higher expected values of case-specificity
score (Figure 1a,b). We then went on to compare the distribution of case- and control-specificity
scores for protein-altering variants inside genes implicated in T2D/obesity and inside all other
genes. Surprisingly, we observed no significant difference in the distributions of both Score1 and
Score2 (Figure 1c). However, for both variant groups the number of variants with positive Score1
values (i.e., case-specific ones) is much greater than expected by chance (Figure 1d, OR = 1.44/1.31
(implicated/non-implicated); empirical p-value < 0.001). On the other hand, the number of variants
specific to the control group (i.e., with positive Score2 values) was lower in both variant classes
(Figure S4). These results indicate that while there is no significant enrichment of case-specific
variants inside implicated genes compared to the other ones, protein-altering exome variants are
overrepresented in the case group and underrepresented in the control one. Hence, we further
focused both on two groups of variants with the highest causal potential: (i) protein-altering variants
inside known T2D and obesity genes; and (ii) highly case-specific variants with low alternative allele
frequency (Figure 1e).
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obesity genes (Table 2, Section 3; see Methods). Among these w found rs328 in the LPL gene,
coding for lipoprotein lipase, associ ted with T2D and obesity simultaneously (Table 2). The minor
allele of rs328 was previously shown to be associated with elevated LDL an decre sed HDL; moreover,
a recent fine-mapping study su gested its role in the pathogenesis of T2D [34]. We also identified
rs6271 in the DBH gene, and rs62618693 in the QSER1 gene as sp cific markers for obesity. DBH
is a gene encoding a dopamine β-hydroxylase (DβH) that catalyzes the conversion of dopamine
to norepinephrine, which functions both as a hormone and as the main neurotransmitter of the
sympathetic nervous system. Earlier it was shown that the rs6271 polymorphic variant affects the
plasma DβH activity [35]. This variant has been recently implicated in the regulation of blood pressure
levels [36]. Importantly, the rs62618693 variant in QSER1 has also been recently discovered as a
T2D marker using fine-mapping of coding variants [34]. Only one variant inside known causal
genes (rs2233984 in the C6orf15 gene) was identified as a specific T2D marker when comparing T2D
and control groups. This variant is also significantly associated with height [33]. However, three
additional marker variants (rs9379084 in RREB1, rs61737764 in ITGB6, and rs17801742 in COL2A1)
were discovered when comparing T2D patients over control and obese groups together. The RREB1
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gene encodes a transcription factor that binds to RAS-responsive elements (RREs) of gene promoters.
Earlier it was demonstrated that RREB-1 exerts a repressive activity on the HLA-G and it was also
described as a coactivator of calcitonin, c-erbB2, and secretin genes [37–40]. Recent studies have
shown the association of variant rs9379084 of RREB1 gene with fat distribution, fasting glucose [41,42],
and strong association with T2D [10,34,43]. ITGB6 gene encodes an integrinβ-6 that is a transmembrane
glycoprotein receptors. The rs61737764 variant in ITGB6 has not been described as a T2D marker;
however, it is in modest LD with another previously described non-coding T2D variant, rs7593730.
We then turned to investigate another class of likely causal variants, i.e., the case-specific ones
(Table 2, Section 4). We first focused on variants that are rare in the population (SPBU MAF < 0.02) as
the major class prioritized by our scoring method (Figure 1). We designed a statistical approach to more
accurately estimate the significance of case-specific variant association by calculating the empirical
probability of the case-specificity score given known MAF in the population, P (Score1 ≥ N|MAF)
(see Statistical analysis section in the Methods). Out of rare case-specific variants, we discovered
rs139972217 in TMC8, rs61758785 in RAD51B, rs34042554 in PCDHA1, and rs144183813 in PLEKHA5
as the most significant candidates (padj < 0.001). The TMC8 gene encodes for a transmembrane protein,
playing a role in diverse skin diseases. Variants at the TMC6-TMC8 locus have been associated with the
levels of glycated haemoglobin (HbA1c), a common biomarker that is used for diagnostics of T2D [44].
Expression levels of another gene harboring association signal, PLEKHA5, are linked to seroconversion
behind type 1 diabetes [45]. These data indicate potential high relevance of the identified variants for
pathogenesis of T2D and obesity.
Out of exome variants with intermediate frequency (0.02 < SPBU MAF < 0.1) with high
case-specificity score and statistical support, we found rs11863726 in HBQ1 and rs112984085 in VAV3
which were associated with T2D and obesity compared to controls, and rs685523 in ADAMTS13 as a
specific marker for T2D. HBQ1 gene encodes the hemoglobin subunit theta 1 that is expressed only
in human fetal erythroid tissue. The function of this gene is poorly understood. No association
for polymorphism of HBQ1 gene with T2D or other endocrine disorders has been described
previously. The gene of guanine nucleotide exchange factors VAV3 is a member of the VAV family of
proto-oncogenes. VAV3 gene has an impact on angiogenesis, cytoskeleton organization and function,
regulation of immune system which renders it a potentially relevant gene for molecular pathology
behind T2D [46]. The ADAMTS13 gene codes a multimeric plasma glycoprotein that plays a critical
role in platelet adhesion and aggregation on vascular lesions. Previously it was shown that the
circulating von Willebrand factor (VWF) concentrations are elevated in T2D patients, and long-term
studies of T2D patients have linked VWF to the development of both microvascular and macrovascular
disease [47–49]. VWF has been found to be a risk marker for death in T2D [50,51]. The mechanisms
behind elevated VWF concentrations in T2D remain unclear, however, these facts imply a potential
role of ADAMTS13 in the pathogenesis of the disease. Overall, all three genes described above seem as
relevant targets for further genetic and mechanistic studies.
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Table 2. Main markers for obesity and type 2 diabetes (T2D) identified by exome analysis.
Test Position rsID Gene Effect p MAF padj * OR/β Comment
1. Replication of Association (SNP-Level) with Binary/Quantitative Traits
BMI vs. all variants
chr2:272203:C>T rs11553746 ACP1 Missense variant 0.012 0.352 - 3.92
chr14:60928201:G>A rs1956549 C14orf39 Intron variant 0.013 0.073 - 2.60
chr16:24578458:T>C rs7195386 RBBP6 Splice variant 0.029 0.473 - −1.24 [11]
OB vs. control chr5:180166677:G>A rs11960429 OR2Y1 Missense variant 0.043 0.014 - 13.6
T2D vs. C, T2D vs. OBC
chr6:7231843:G>A rs9379084 RREB1 Missense variant 0.013, 0.042 0.097 - 0.26, 0.35 [10,34]
chr12:49399132:G>C rs1126930 PRKAG1 Missense variant 0.041, 0.037 0.032 0.09,0.09 [9,25]
2. Association with Quantitative Traits **
BMI vs. all variants chr16:69752464:C>G rs689452 NQO1 Intron variant 9 × 10−6 0.129 - 2.04 Associated with height [33]
3. Association with Protein-Altering Variants in Known Genes (0.01 < SPBU MAF < 0.1)
OB + T2D vs. control chr8:19819724:C>G rs328 LPL Stop gained 0.023 0.065 - 0.26 Recently associated [34]
OB vs. control
chr9:136522274:C>T rs6271 DBH Missense variant 0.043 0.041 - 13.5 Associated with BP *** [36]
chr11:32956:C>T rs62618693 QSER1 Missense variant 0.021 0.038 - 10.1 Recently associated [34]
T2D vs. control
chr6:7231843:G>A rs9379084 RREB1 Missense variant 0.013 0.097 - 0.26 Recently associated [34]
chr6:31079264:C>T rs2233984 C6orf15 Missense variant 0.030 0.067 - 0.31 Associated with height [33]
T2D vs. OBC
chr2:160994293:C>T rs61737764 ITGB6 Missense variant 0.035 0.007 - 12.1 Linked withrs7593730
chr6:7231843:G>A rs9379084 RREB1 Missense variant 0.042 0.097 - 0.35
4. Association with Case-Specific Exome Variants (SPBU MAF < 0.1)
OB vs. control
chr5:140168291:T>C rs34042554 PCDHA1 Missense variant 0.003 0.017 1.0 × 10−4 25.1
chr14:69061228:G>A rs61758785 RAD51B Missense variant 0.035 0.007 1.7 × 10−4 12.6
chr12:19408017:G>A rs144183813 PLEKHA5 Missense variant 0.015 0.007 1.7 × 10−4 17.9 Gene expression affects T1D † [45]
T2D vs. OBC chr12:48376869:T>C rs17801742 COL2A1 Splice variant 3.1 × 10−4 0.089 8.5 × 10−5 10.4 Associated with height [33]
OB + T2D vs. control
chr16:230578:A>G rs11863726 HBQ1 Splice variant 3.9 × 10−4 0.094 8 × 10−5 22.8
chr1:108119007:G>C rs112984085 VAV3 Intron variant 7.1 × 10−4 0.063 4.8 × 10−4 21.3
T2D vs. C, T2D vs. OBC
chr9:136310908:C>T rs685523 ADAMTS13 Missense variant 2.7 × 10−4, 1.6 × 10−5 0.083 7 × 10−5, 1 × 10−6 26.0, 38.9
chr17:76136994:C>T rs139972217 TMC8 Missense variant 0.032, 0.006 0.009 1.4 × 10−4, 9.9 × 10−5 11.6, 17.9 Gene associated with HbA1c [44]
C—control group, OBC—obese and controls pooled together; *—adjusted p-value for selected variants was obtained by bootstrap test conditioned on true population minor allele
frequency (MAF) (see Statistical analysis section in the Methods); **—all individuals were pooled for quantitative trait analysis; ***—BP—blood pressure; †—T1D—type 1 diabetes; OR:
odds ratio.
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4. Discussion
Type 2 diabetes is one of the severe chronic endocrine diseases, whose prevalence is steadily
increasing worldwide [1–4]. Obesity is strongly correlated with T2D and increases the odds of
development of T2D; however, both shared and unique genetic and environmental factors shape the
risk of T2D and obesity. Large-scale genetic studies have identified numerous loci associated with T2D
and obesity, with the most recent efforts involving hundreds of thousands of individuals of various
ancestry [9–11,34]. However, genetic variants affecting the risk of a disease in less studied population
groups might substantially differ from the ones observed in these studies. Hence, additional genetic
studies in these populations are needed to identify common and specific disease markers (exemplified
in [52]).
In our study we applied a multi-perspective approach to identify candidate markers of T2D
and obesity in a cohort of Russian patients with T2D and obesity. We applied both conventional
SNP-level and gene-level association tests, as well as novel strategies to identify variants associated
with T2D, obesity, and relevant quantitative traits (BMI, WHR, glucose, and triglyceride concentration).
We present an efficient approach to search for novel candidate markers in WES data that are applicable
in smaller samples. This approach is based on rational filtering of protein-altering genetic variants and
prioritization of case- or control-specific genetic variants, i.e., the ones with the highest potential of
being causal for the disease. We show that, while this approach has low power to identify common
variants with low OR, it efficiently prioritizes variants of intermediate and low frequency with higher
OR (Figure 1a,b). In order to decrease false discovery probability, which is quite substantial without
any additional filters (P (Score ≥ 20) = 0.047 for a variant with MAF = 0.02 and OR = 1), we also apply
additional p-value adjustments that allow for selection of statistically justified rare variants with low
or moderate type 1 error probability.
The application of our approach allowed us to identify potential common and specific markers
for diabetes and obesity. We present evidence for potential association of variants in RREB1, ITGB6,
COL2A1, TMC8 and ADAMTS13 genes with T2D, and of variants in HBQ1, LPL, and VAV3 with both
diabetic and non-diabetic obesity. Importantly, some variants (namely, rs685523 in ADAMTS13 and
rs61737764 in ITGB6) were specific to the group of T2D patients. It is probable that these markers
control the processes initiated by specific metabolic cascades which are less relevant for non-diabetic
obesity. Moreover, we observed candidate association of rs6271 in the DBH gene, rs62618693 in the
QSER1 gene, and variants in PCDHA1, RAD51B, and PLEKHA5 with non-T2D-linked obesity. It can be
assumed that these markers are potentially involved in the development of obesity as an independent
condition. However, this hypothesis requires further confirmation.
It is important to note that our analysis strategy allowed us to identify several candidate markers
of T2D which have been showed to be significantly associated with the phenotype in one of the most
recent fine-mapping studies (e.g., rs328 in LPL, rsrs62618693 in QSER1, and rs9379084 in RREB1) [34].
As such, our strategy based on filtering for protein-altering variants inside implicated genes can
enhance identification of candidate coding markers in smaller samples. On the other hand, we observed
that protein-altering variants are significantly overrepresented in cases compared to control individuals
both inside and outside known disease-relevant genes (Figure 1b). While this result may be at least
partially explained by weak genetic linkage which could not be resolved given a small sample size,
recent results [34] indicate that numerous coding markers for T2D actually lie outside of known
disease genes. Hence, it seems useful to consider damaging variants inside both implicated and
non-implicated genes in exome sequencing-based studies. Importantly, most of the rare variants
identified by case-specific scoring approach are actually annotated as damaging missense mutations in
non-implicated genes, i.e., they belong to the protein-altering class.
In our study, we observed several highly case-specific variants in genes previously not directly
linked to T2D and/or obesity (e.g., TMC8, PCDHA1, PLEKHA5, HBQ1, VAV3, and ADAMTS13).
While many of these variants lack functional validation and were not reported in other studies,
genetic alterations or expression changes of some of the corresponding genes are associated with
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diabetes-related glycemic traits (e.g., HbA1c levels for TMC8 [44] and T1D-related seroconversion
for PLEKHA5 [45]). Thus, these genes may be selected as potential candidates for further functional
investigations and replication of association results.
5. Conclusions
Our study shows that whole exome analysis can serve as a reasonable approach for identifying
genetic markers of a complex disease even in limited samples. Using our multi-perspective analysis
strategy, we have discovered some reasonable candidate loci and SNPs that might play an important
role in the pathogenesis of T2D and obesity in the Russian population. Overall, rational filtering
and ranking of potentially causal variants offers a valuable strategy for the candidate disease marker
discovery by exome sequencing in poorly studied populations, especially if large-scale genetic studies
are lacking. As such, this approach may assist in disease gene identification for polygenic traits.
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